Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.63 |
| ▸ | CA2 | P00918 | 9/20 | 0.63 |
| ▸ | CA12 | O43570 | 5/20 | 0.63 |
| ▸ | CA9 | Q16790 | 5/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | MMP2 | P08253 | 2/20 | 0.47 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3368185 | 0.88 | CA12 (0.57) | CA1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL29695319 | 0.84 | CA12 (0.65) | CA1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL991695 | 0.82 | CA1 (0.62) | CA1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL21625802 | 0.80 | CA1 (0.77) | CA1CA2CA12CA9 | |
| SCHEMBL21625809 | 0.80 | CA1 (0.76) | CA1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL1519545 | 0.80 | CA1 (0.57) | CA1CA2SMN1; SMN2ALDH1A1EPHX2 | |
| Hydrochloric Acid SCHEMBL3371576 | 0.79 | MMP1 (0.54) | CA1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL15616293 | 0.79 | CA12 (0.61) | CA1CA2CA12CA9SMN1; SMN2 | |
| SCHEMBL15199006 | 0.78 | CA1 (1.00) | CA1CA2CA12CA9 | |
| SCHEMBL16604568 | 0.77 | CA1 (0.52) | CA1CA2CA12CA9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2010048340-A2 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | LEAD THERAPEUTICS, INC. (US) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105607-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, ALG8, ALG1 | CA1 2552/4885CA2 3594/4885CA12 993/4885 |
| US-20120252741-A1 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS | ASNS, DNPEP, ALG8 | CA1 2394/4885CA2 2937/4885CA12 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.